Parkinson's disease vaccine??

View this email as a webpage | Add no-reply@michaeljfox-email.org to your address book | Contact Us Vaccine Approaches Continue Showing Promise in Clinical Testing Last week biotechnology company Prothena announced positive safety results in a Phase I study of its Parkinson's vaccine. By introducing an antibody (the body's natural disease fighters), Prothena's vaccine could potentially slow or stop disease progression. This announcement is the second of its kind in recent months. In July, MJFF-grantee AFFiRiS also shared positive safety results of its own vaccine approach to treating Parkinson's.   Read More > From iPhone to Genome: How Patient Data Is Changing Parkinson's Research Join us for our Third Thursdays Webinar series. Hear expert discussion, and ask your questions. April 16, 2015, at 12 p.m. ET PPMI Expands Genetic Cohort The Parkinson's Progression Markers Initiative (PPMI) is expanding to study individuals who have a mutation of the GBA gene. A GBA mutation is more common among certain populations, specifically those of Ashkenazi (Eastern European) Jewish descent.  Read More > Why I Run: Tour de Fox Endurance Athlete Opens Up about Inspiration  This spring, Sam Fox (no relation to Michael) will embark on Tour de Fox: a 14,000-mile hiking and biking journey across the United States. Sam is inspired by his mom, Lucy, who hasn't let her Parkinson's disease curb her love of the outdoors. Read More > New Technologies Propel Parkinson's Research Forward This month, MJFF joined Apple Computer and Sage Bionetworks in announcing new technologies that hold the potential to streamline and advance patient data collection. Read More >